Shanghai Bahe Pharma

Shanghai Bahe Pharma is a clinical-stage biotechnology company based in Shanghai, China, dedicated to the discovery and development of next-generation small molecule drugs. The company leverages a proprietary structure-based drug design (SBDD) platform to target complex protein-protein interactions and difficult-to-drug oncogenic drivers. Its primary focus is on the RAS signaling pathway, with a pipeline featuring inhibitors for KRAS G12D, SOS1, and SHP2. The lead candidate, BH-001, is a highly selective KRAS G12D inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors. Bahe Pharma aims to provide transformative therapies for patients with high unmet medical needs in oncology.